Pacritinib for relapsed or refractory Waldenström macroglobulinemia

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

This trial will test whether the oral drug pacritinib can safely reduce disease and symptoms in adults whose Waldenström macroglobulinemia has returned or did not respond to prior treatment.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Dana-Farber Cancer Institute (Academic / other)
• Drugs / interventions: pacritinib
• Locations: 1 site (Boston, Massachusetts)
• Trial ID: NCT06986174 on ClinicalTrials.gov

What this trial studies

This is a single-arm, open-label Phase 2 trial enrolling about 30 adults with symptomatic relapsed or refractory Waldenström macroglobulinemia to receive oral pacritinib. Pacritinib blocks JAK2 and IRAK1, pathways thought to support WM cell survival, and participants will be treated for up to four years with regular clinical visits, blood and urine tests, imaging, ECGs, and bone marrow exams. The trial will collect safety data and measure anti-tumor activity using standard WM response criteria, including changes in IgM and blood counts. Participants will be followed for two years after treatment or until they start a new therapy.

Who should consider this trial

Good fit: Adults (≥18 years) with symptomatic Waldenström macroglobulinemia that has relapsed or is refractory to prior therapy, who meet consensus criteria for treatment, have ECOG ≤2, and have adequate organ and marrow function are the intended participants.

Not a fit: Patients who do not yet require treatment, those with severe organ dysfunction or blood counts below the inclusion thresholds, or whose disease biology does not depend on JAK2/IRAK1 signaling may not receive benefit from pacritinib.

Why it matters

Potential benefit: If effective, pacritinib could provide a new oral targeted option that lowers IgM, improves blood counts, and reduces symptoms in patients with relapsed or refractory WM.

How similar studies have performed: Pacritinib is FDA-approved for myelofibrosis and the JAK2/IRAK1 rationale supports testing in WM, but clinical experience with pacritinib specifically in Waldenström macroglobulinemia is limited and this application is relatively novel.

Eligibility criteria

Inclusion Criteria:

* Age ≥18 years
* ECOG performance status ≤2
* Clinicopathological diagnosis of Waldenström Macroglobulinemia
* Symptomatic disease meeting criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenström macroglobulinemia. At least one of the following:

  * constitutional symptoms: recurrent fever, night sweats, fatigue or weight loss
  * progressive or symptomatic lymphadenopathy or splenomegaly
  * hemoglobin ≤10 g/dL
  * platelet count ≤100 k/uL
  * hyperviscosity syndrome
  * symptomatic peripheral neuropathy
  * systemic amyloidosis
  * renal insufficiency
  * symptomatic cryoglobulinemia
* Serum IgM level ≥ 2 times the upper limit of normal
* Participants must meet the following organ and marrow functions as defined below:

  * absolute neutrophil count ≥0.5 k/uL without growth factor within 7 days
  * platelet count ≥50 k/uL without platelet transfusion within 7 days
  * total bilirubin ≤1.5 times the upper limit of normal or ≤3 times the upper limit of normal with documented liver involvement, hemolysis or Gilbert's disease
  * AST (SGOT) and ALT (SGPT) ≤2.5 times the upper limit of normal or ≤5 times the upper limit of normal with documented liver involvement
  * Creatinine clearance ≥30 ml/min using Cockcroft/Gault equation
* Ability to understand and the willingness to sign a written informed consent document. (Providing consents in as many languages as possible is encouraged)
* At least 2 prior lines of treatment for Waldenström Macroglobulinemia. Participants must either be BTK inhibitor exposed or not be a candidate for BTK therapy.
* Women of childbearing potential: Females of childbearing potential (FCBP) will be required to use two highly effective forms of contraception simultaneously or will remain abstinent from heterosexual intercourse during the following periods related to this study:

  1. while participating in the study; and 2) for at least three months (90 days) after discontinuation from the study. FCBP must be referred to a qualified provider of contraceptive methods if needed.

Exclusion Criteria:

* Current history of uncontrolled HIV
* Patients with a known history of HIV must have a viral load assessed for eligibility and must be on a stable antiretroviral regimen that can be administered concurrent with pacritinib.
* Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection based on criteria below

  * Hepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (antiHBc) and negative HBsAg require hepatitis B polymerase chain reaction (PCR) evaluation before enrollment. Patients who are hepatitis B PCR positive will be excluded.
  * Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before enrollment. Patients who are hepatitis C RNA positive will be excluded.
* Participants with chronic liver disease and hepatic impairment meeting Child-Pugh class B or C (Appendix B)
* Participants who are pregnant, breast feeding, or planning to become pregnant while enrolled in this study or within 3 month after last study dose (2 weeks for breastfeeding)
* Current CNS involvement by WM
* Active alcohol or drug abuse
* Concurrent administration of medications that are moderate or strong inhibitors or inducers of CYP3A within 14 days or 5 half-lives, whichever is shorter, prior to first dose of study drug.
* Concurrent participation in another therapeutic clinical trial
* History of another malignancy, except adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, localized prostate cancer, or other adequately treated cancer currently in complete remission
* Prior or ongoing clinically significant illness, including active infections requiring antibiotics, of medical condition that, in the investigator's opinion, could affect the safety of the patient; alter the absorption, distribution, metabolism or excretion of the study drug; or impair the assessment of study results
* Inability to swallow pills
* Significant cardiovascular disease defined as:

  * Unstable angina, or
  * History of myocardial infarction within 6 months prior to planned start
  * Previously documented left ventricular ejection fraction (LVEF) by any method of ≤ 45% in the 12 months prior to planned start; assessment of LVEF via echocardiogram or multigated acquisition (MUGA) scan during screening should be performed in selected patients as medically indicated, or
  * Any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or
  * Uncontrolled or symptomatic arrhythmias
* Prolonged QT Interval with baseline QTc \>480 msec using the Bazette formula
* Ongoing, active infection.
* Active bleeding requiring blood transfusion or other medical intervention. Participants requiring anticoagulation therapy are not excluded.

Where this trial is running

Boston, Massachusetts

• Dana Farber Cancer Institute — Boston, Massachusetts, United States (Recruiting)

Study contacts

• Principal investigator: Shayna Sarosiek, MD — Dana-Farber Cancer Institute
• Study coordinator: Shayna Sarosiek, MD

Conditions Waldenström Macroglobulinemia; Lymphoplasmacytic Lymphoma; B-Cell Lymphoproliferative Disorder; Indolent Lymphoma; Lymphoma